Mangalam Drugs and Organics Limited has announced that it has received a significant repeat export order from one of its reputed international clients for the supply of Anti-Malarial Active Pharmaceutical Ingredient (API). The aggregate value of the order stands at approximately Rs 15 crore, the company stated in an exchange filing.
According to the disclosure submitted under Regulation 30 of SEBI (LODR) Regulations, 2015, the order will be executed over the next 2–4 months. The company clarified that the purchasing entity is an international client, and that neither the promoter nor promoter group has any interest in the awarding entity, confirming that the transaction does not fall under related-party provisions.
Mangalam Drugs added that the repeat order highlights strong customer trust and reinforces the company’s position in the global pharmaceutical market. It further stated that the order is expected to contribute positively to revenue visibility and the company’s growth trajectory in upcoming quarters.
The company reiterated its commitment to supplying high-quality pharmaceutical products to domestic and international markets while continuing to enhance shareholder value.
